COMPARISON OF THE CLINICAL ACTIVITY OF MESULERGINE AND PERGOLIDE IN THE TREATMENT OF HYPERPROLACTINAEMIA

Publisher Website
Google Scholar
Abstract
The clinical activity of the new ergoline, mesulergine, was compared to pergolide in the treatment of hyperprolactinemia. Mesulergine was given to 22 women and 5 men with hyperprolactinemia. Serum prolactin was subtantially lowered in 10 women; 2 subsequently conceived and completed normal pregnancies. Twelve women stopped treatment due to side-effects, usually nausea and vomiting, or inadequate responses. The side-effects were generally similar to those on bromicriptine; in 1 patient they were better and in 4 worse than on bromocriptine. The male patients were more tolerant of mesulergine; substantial falls in serum prolactin were seen with evidence of tumor shrinkage. Twenty-seven women with hyperprolactinemia received pergolide; serum prolactin was lowered or normalized in 16. Side-effects necessitating cessation of treatment were similar to those seen with bromocriptine. Nevertheless, 4 women tolerated pergolide better than bromocriptine and 2 women adequately treated with mesulergine had previously been intolerant of pergolide. Apparently, both pergolide and mesulergine may be useful and effective drugs in the treatment of hyperprolactinemia as alternatives to bromocriptine.